<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href='static/style.xsl' type='text/xsl'?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T10:55:41Z</responseDate><request verb="GetRecord" identifier="oai:ecommons.cornell.edu:1813/117224" metadataPrefix="dim">https://ecommons.cornell.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:ecommons.cornell.edu:1813/117224</identifier><datestamp>2026-05-15T19:50:09Z</datestamp><setSpec>com_1813_35</setSpec><setSpec>col_1813_47</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Ye, Tina</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="chair" lang="en_US">DeLisa, Matthew</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Mao, Yuxin</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Alabi, Christopher</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2025-06-30T22:03:54Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2024-12</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Submission ID: 14790</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Publication ID: 31641557</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1813/117224</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="doi">http://doi.org/10.7298/cvf2-h575</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="bibid">16922039</dim:field>
   <dim:field mdschema="dc" element="description" lang="en_US">162 pages</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Proteome editing offers a powerful approach for targeted protein modulation that enables post-translational degradation, stabilization, activation, or relocalization of proteins of interest (POIs) within cells. One promising proteome editing modality is ubiquibodies (uAbs), which are chimeric proteins composed of a POI-binding domain fused to an E3 ubiquitin ligase or E3 adaptor, redirecting the otherwise stable POI to the proteasome for degradation. Traditional uAb technology has relied heavily on pre-existing binding domains with affinity and specificity for a limited number of targets. To overcome this limitation, we leveraged a protein language model (pLM)-driven algorithm, SaLT&amp;PepPr, to computationally design “guide” peptides with affinity for β-catenin, a validated cancer target that has remained beyond the reach of conventional therapeutic approaches. These peptides were fused to the catalytic domain of the human E3 ligase CHIP, creating peptide-guided uAbs. When expressed in colorectal cancer cells, these uAbs selectively degraded cytosolic and nuclear β-catenin, the pathogenic subpopulation associated with driving oncogene expression, while preserving the normal membrane-associated subpopulation, which is protective and maintains tissue integrity. Selective knockdown of pathogenic β-catenin disrupted Wnt/β-catenin signaling and impaired tumor cell proliferation. Additionally, we demonstrated the degradation of β-catenin in BALB/c mice using an optimized uAb that was delivered intravenously as LNP-encapsulated mRNA. Collectively, our results highlight the potential of uAbs to selectively target and degrade pathogenic proteins, paving the way for the development of peptide-programmable biologic modulators for other disease-associated proteins.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="embargo">2027-01-09</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en</dim:field>
   <dim:field mdschema="dc" element="rights" lang="*">Attribution-NonCommercial-NoDerivatives 4.0 International</dim:field>
   <dim:field mdschema="dc" element="rights" qualifier="uri" lang="*">https://creativecommons.org/licenses/by-nc-nd/4.0/</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">biodegraders</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">E3 ubiquitin ligase</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">proteome editing</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">target protein degradation</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Ubiquibody</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Wnt/β-catenin signaling</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">ENGINEERING PROGRAMMABLE PROTEIN DEGRADERS FOR SELECTIVE ELIMINATION OF TARGET PROTEINS</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">dissertation or thesis</dim:field>
   <dim:field mdschema="dc" element="relation" qualifier="localuri">https://newcatalog.library.cornell.edu/catalog/16922039</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline">Chemical Engineering</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="grantor">Cornell University</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="level">Doctor of Philosophy</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">Ph. D., Chemical Engineering</dim:field>
   <dim:field mdschema="dcterms" element="license">https://hdl.handle.net/1813/59810.2</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="collection" authority="https://cornell-ecommons.eks.prod.4science.cloud/handle/1813/47" confidence="600">Cornell Theses and Dissertations</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="author">Ye, Tina</dim:field>
   <dim:field mdschema="cris" element="virtualsource" qualifier="collection">5893a6ea-7af3-41d7-abc6-04bcd26ab5df</dim:field>
   <dim:field mdschema="others" element="access-status">embargo</dim:field>
   <dim:field mdschema="others" element="access-status">embargo</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="1c36772c-0891-4df0-bd33-6fbfc6379f0d">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>en&lt;/Language>
   	&lt;Title>ENGINEERING PROGRAMMABLE PROTEIN DEGRADERS FOR SELECTIVE ELIMINATION OF TARGET PROTEINS&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2024-12&lt;/PublicationDate>
   	&lt;DOI>http://doi.org/10.7298/cvf2-h575&lt;/DOI>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Ye, Tina&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;License>https://creativecommons.org/licenses/by-nc-nd/4.0/&lt;/License>
    &lt;Keyword>biodegraders&lt;/Keyword>
    &lt;Keyword>E3 ubiquitin ligase&lt;/Keyword>
    &lt;Keyword>proteome editing&lt;/Keyword>
    &lt;Keyword>target protein degradation&lt;/Keyword>
    &lt;Keyword>Ubiquibody&lt;/Keyword>
    &lt;Keyword>Wnt/β-catenin signaling&lt;/Keyword>
   	&lt;Abstract>Proteome editing offers a powerful approach for targeted protein modulation that enables post-translational degradation, stabilization, activation, or relocalization of proteins of interest (POIs) within cells. One promising proteome editing modality is ubiquibodies (uAbs), which are chimeric proteins composed of a POI-binding domain fused to an E3 ubiquitin ligase or E3 adaptor, redirecting the otherwise stable POI to the proteasome for degradation. Traditional uAb technology has relied heavily on pre-existing binding domains with affinity and specificity for a limited number of targets. To overcome this limitation, we leveraged a protein language model (pLM)-driven algorithm, SaLT&amp;amp;PepPr, to computationally design “guide” peptides with affinity for β-catenin, a validated cancer target that has remained beyond the reach of conventional therapeutic approaches. These peptides were fused to the catalytic domain of the human E3 ligase CHIP, creating peptide-guided uAbs. When expressed in colorectal cancer cells, these uAbs selectively degraded cytosolic and nuclear β-catenin, the pathogenic subpopulation associated with driving oncogene expression, while preserving the normal membrane-associated subpopulation, which is protective and maintains tissue integrity. Selective knockdown of pathogenic β-catenin disrupted Wnt/β-catenin signaling and impaired tumor cell proliferation. Additionally, we demonstrated the degradation of β-catenin in BALB/c mice using an optimized uAb that was delivered intravenously as LNP-encapsulated mRNA. Collectively, our results highlight the potential of uAbs to selectively target and degrade pathogenic proteins, paving the way for the development of peptide-programmable biologic modulators for other disease-associated proteins.&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>